Verona Pharma Plc Revenue Growth Rates (VRNA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Verona Pharma Plc  (NASDAQ: VRNA)
 

VRNA's Revenue Growth by Quarter and Year

Verona Pharma Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRNA Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 103.14
1st Quarter March 76.26
FY 179.40





VRNA Revenue second quarter 2025 Y/Y Growth Comment
Verona Pharma Plc in the second quarter 2025 achieved Revenue of $ 103.14 millions compare to recorded in same quarter a year ago.

According to the results reported in the second quarter 2025, Verona Pharma Plc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Verona Pharma Plc' s Revenue no change of 0% ranks overall at the positon no. in the second quarter 2025.


VRNA Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Verona Pharma Plc's second quarter 2025 Revenue $ 103.14 millions VRNA's Income Statement
Verona Pharma Plc's second quarter 2024 Revenue $ 0.00 millions Quarterly VRNA's Income Statement


VRNA Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 552.31 % - -
3rd Quarter September - - - -
2nd Quarter June 35.25 % - - -
1st Quarter March 108.02 % - - -
FY (Year on Year)   - - - -


Back to VRNA Growth rate Comparisons >> Back to VRNA Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2024)   (Mar 31 2023)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2024)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Verona Pharma Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
551.76 % 99.01 % -100 %
(Dec 31 2024)  


VRNA's II. Quarter Q/Q Revenue Comment
Verona Pharma Plc achieved in the II. Quarter 2025 below company average Revenue jump of 35.25% quarter on quarter, to $ 103.14 millions.

Although the II. Quarter 2025 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the % growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Verona Pharma Plc's Revenue growth quarter on quarter, overall rank is 328.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #82
Overall #328
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #82
Overall #328
Revenue Q/Q Growth Statistics
High Average Low
551.76 % 99.01 % -100 %
(Dec 31 2024)  


VRNA's II. Quarter Q/Q Revenue Comment
Verona Pharma Plc achieved in the II. Quarter 2025 below company average Revenue jump of 35.25% quarter on quarter, to $ 103.14 millions.

II. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Verona Pharma Plc's Revenue growth quarter on quarter, overall rank is 328.


Verona Pharma Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 221.67 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment


Verona Pharma Plc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment


Verona Pharma Plc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VRNA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Carlisle Companies Incorporated-0.08%$ -0.076 millions
Zimvie Inc -0.13%$ -0.128 millions
Community Health Systems Inc -0.22%$ -0.223 millions
Bruker Corporation-0.46%$ -0.462 millions
Integra Lifesciences Holdings Corp-0.61%$ -0.615 millions
Adapthealth Corp -0.70%$ -0.695 millions
Perrigo Company Plc-0.79%$ -0.789 millions
Organon and Co -0.81%$ -0.809 millions
Castle Biosciences Inc -0.94%$ -0.936 millions
Vaso Corporation-0.96%$ -0.963 millions
Profound Medical Corp -0.99%$ -0.985 millions
Capsovision Inc -1.13%$ -1.126 millions
Avantor Inc -1.14%$ -1.139 millions
Inspiremd Inc -1.35%$ -1.352 millions
Align Technology inc -1.51%$ -1.509 millions
Teladoc Health Inc -1.64%$ -1.641 millions
Supernus Pharmaceuticals inc -1.71%$ -1.706 millions
Encision Inc -1.73%$ -1.729 millions
Cytek Biosciences Inc -1.80%$ -1.796 millions
Merck and Co Inc -1.90%$ -1.899 millions
Bioventus Inc -1.98%$ -1.978 millions
Alkermes Plc -2.12%$ -2.123 millions
Anteris Technologies Global Corp -2.22%$ -2.215 millions
Surmodics Inc -2.55%$ -2.551 millions
Nrc Health-2.81%$ -2.807 millions
Rxsight Inc -3.09%$ -3.095 millions
Apyx Medical Corp-3.57%$ -3.567 millions
Quidelortho Corp-3.63%$ -3.626 millions
Lantheus Holdings Inc -4.00%$ -4.003 millions
Quipt Home Medical Corp -4.07%$ -4.065 millions


About Verona Pharma Plc Revenue Growth Rates (VRNA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Verona Pharma Plc (CIK 1657312).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001657312-25-000026
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Verona Pharma Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.